Nutraceuticals in Lipid-Lowering Treatment

A Narrative Review on the Role of Chitosan

Angelo Maria Patti, Niki Katsiki, Dragana Nikolic, Khalid Al-Rasadi, Manfredi Rizzo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids, lipoproteins, blood pressure, glucose, and insulin levels and their anti-inflammatory and anti-oxidant effects are documented. However, larger, prospective clinical trials are required to confirm such benefits. Such treatments may be recommended when lipid-lowering drugs are neither indicated nor tolerated as well as in order to achieve therapeutic targets and/or overcome residual CV risk.

Original languageEnglish
Pages (from-to)416-421
Number of pages6
JournalAngiology
Volume66
Issue number5
DOIs
Publication statusPublished - May 21 2015

Fingerprint

Chitosan
Dietary Supplements
Lipids
Incretins
Phytosterols
Prebiotics
Dietary Fiber
Tea
Pharmaceutical Preparations
Lipoproteins
Blood Glucose
Life Style
Anti-Inflammatory Agents
Antioxidants
Research Personnel
Clinical Trials
Insulin
Blood Pressure
Therapeutics
Proteins

Keywords

  • chitosan
  • dietary supplements
  • lipids
  • lipoproteins
  • nutraceuticals

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Nutraceuticals in Lipid-Lowering Treatment : A Narrative Review on the Role of Chitosan. / Patti, Angelo Maria; Katsiki, Niki; Nikolic, Dragana; Al-Rasadi, Khalid; Rizzo, Manfredi.

In: Angiology, Vol. 66, No. 5, 21.05.2015, p. 416-421.

Research output: Contribution to journalArticle

Patti, Angelo Maria ; Katsiki, Niki ; Nikolic, Dragana ; Al-Rasadi, Khalid ; Rizzo, Manfredi. / Nutraceuticals in Lipid-Lowering Treatment : A Narrative Review on the Role of Chitosan. In: Angiology. 2015 ; Vol. 66, No. 5. pp. 416-421.
@article{e447743d75724ce4a71af9e19d2e9b97,
title = "Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan",
abstract = "Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids, lipoproteins, blood pressure, glucose, and insulin levels and their anti-inflammatory and anti-oxidant effects are documented. However, larger, prospective clinical trials are required to confirm such benefits. Such treatments may be recommended when lipid-lowering drugs are neither indicated nor tolerated as well as in order to achieve therapeutic targets and/or overcome residual CV risk.",
keywords = "chitosan, dietary supplements, lipids, lipoproteins, nutraceuticals",
author = "Patti, {Angelo Maria} and Niki Katsiki and Dragana Nikolic and Khalid Al-Rasadi and Manfredi Rizzo",
year = "2015",
month = "5",
day = "21",
doi = "10.1177/0003319714542999",
language = "English",
volume = "66",
pages = "416--421",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Nutraceuticals in Lipid-Lowering Treatment

T2 - A Narrative Review on the Role of Chitosan

AU - Patti, Angelo Maria

AU - Katsiki, Niki

AU - Nikolic, Dragana

AU - Al-Rasadi, Khalid

AU - Rizzo, Manfredi

PY - 2015/5/21

Y1 - 2015/5/21

N2 - Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids, lipoproteins, blood pressure, glucose, and insulin levels and their anti-inflammatory and anti-oxidant effects are documented. However, larger, prospective clinical trials are required to confirm such benefits. Such treatments may be recommended when lipid-lowering drugs are neither indicated nor tolerated as well as in order to achieve therapeutic targets and/or overcome residual CV risk.

AB - Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids, lipoproteins, blood pressure, glucose, and insulin levels and their anti-inflammatory and anti-oxidant effects are documented. However, larger, prospective clinical trials are required to confirm such benefits. Such treatments may be recommended when lipid-lowering drugs are neither indicated nor tolerated as well as in order to achieve therapeutic targets and/or overcome residual CV risk.

KW - chitosan

KW - dietary supplements

KW - lipids

KW - lipoproteins

KW - nutraceuticals

UR - http://www.scopus.com/inward/record.url?scp=84928027364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928027364&partnerID=8YFLogxK

U2 - 10.1177/0003319714542999

DO - 10.1177/0003319714542999

M3 - Article

VL - 66

SP - 416

EP - 421

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 5

ER -